SLDB RSI Chart
Last 7 days
-13.9%
Last 30 days
-10.4%
Last 90 days
-10.7%
Trailing 12 Months
47.9%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2022 | 12.2M | 14.8M | 11.2M | 8.1M |
2021 | 0 | 0 | 0 | 13.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 02, 2024 | ganot ilan | acquired | - | - | 1,553 | - |
May 02, 2024 | ganot ilan | sold | -4,772 | 10.33 | -462 | - |
Apr 03, 2024 | smith ian f | acquired | - | - | 3,256 | - |
Jan 29, 2024 | ganot ilan | sold | -1,110 | 7.99 | -139 | - |
Jan 27, 2024 | ganot ilan | acquired | - | - | 388 | - |
Jan 27, 2024 | ganot ilan | acquired | - | - | 3,883 | - |
Jan 11, 2024 | perceptive advisors llc | bought | 18,861,200 | 5.53 | 3,410,710 | - |
Jan 11, 2024 | koppel adam | acquired | 5,000,000 | 5.53 | 904,160 | - |
Jan 11, 2024 | bain capital life sciences investors, llc | acquired | 5,000,000 | 5.53 | 904,160 | - |
Jan 11, 2024 | ra capital management, l.p. | bought | 5,000,000 | 5.53 | 904,160 | - |
Which funds bought or sold SLDB recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 1,145,570 | 1,145,570 | -% |
May 15, 2024 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | new | - | 30,108,500 | 30,108,500 | 0.52% |
May 15, 2024 | GOLDMAN SACHS GROUP INC | new | - | 2,713,920 | 2,713,920 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | new | - | 458,541 | 458,541 | -% |
May 15, 2024 | JANUS HENDERSON GROUP PLC | new | - | 23,934,700 | 23,934,700 | 0.01% |
May 15, 2024 | SILVERARC CAPITAL MANAGEMENT, LLC | added | 122 | 13,997,500 | 17,649,900 | 4.90% |
May 15, 2024 | STATE STREET CORP | added | 64.36 | 702,469 | 976,276 | -% |
May 15, 2024 | MORGAN STANLEY | added | 424 | 269,516 | 295,507 | -% |
May 15, 2024 | FIRST MANHATTAN CO. LLC. | unchanged | - | 955 | 1,771 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 666 | 380,101 | 404,409 | -% |
Unveiling Solid Biosciences Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Solid Biosciences Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.57 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Solid Biosciences Inc News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Revenue | - | - | - | 6.00 | 2.00 | 3.00 | 4.00 | 4.00 | 3.00 |
Operating Expenses | 63.6% | 35.00 | 21.00 | 32.00 | 27.00 | 22.00 | 22.00 | 22.00 | 20.00 |
S&GA Expenses | 6.9% | 8.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 6.00 |
R&D Expenses | 52.0% | 21.00 | 14.00 | 23.00 | 20.00 | 15.00 | 14.00 | 16.00 | 14.00 |
Net Income | 25.8% | -15.15 | -20.41 | -25.09 | -25.33 | -18.61 | -17.98 | -18.69 | -16.90 |
Net Income Margin | -33.6% | -10.62* | -7.95* | -5.89* | -6.60* | -5.30* | - | - | - |
Free Cashflow | -66.1% | -35.34 | -21.27 | -17.01 | -27.37 | -21.53 | -18.66 | -17.45 | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 50.8% | 249 | 165 | 185 | 205 | 230 | 260 | 184 | 208 | 208 | 232 | 249 | 266 | 285 | 171 | 41.00 | 58.00 | 74.00 | 103 | 131 | 96.00 | 120 |
Current Assets | 65.1% | 214 | 130 | 148 | 167 | 191 | 220 | 148 | 170 | 199 | 223 | 239 | 255 | 274 | 159 | 27.00 | 44.00 | 58.00 | 86.00 | 113 | 78.00 | 102 |
Cash Equivalents | 61.3% | 119 | 74.00 | 49.00 | 92.00 | 165 | 155 | 49.00 | 54.00 | 130 | 119 | 110 | 201 | 268 | 155 | 25.00 | 41.00 | 54.00 | 76.00 | 95.00 | 52.00 | 54.00 |
Net PPE | -3.5% | 6.00 | 7.00 | 7.00 | 7.00 | 9.00 | 10.00 | 6.00 | 7.00 | 6.00 | 6.00 | 7.00 | 7.00 | 7.00 | 8.00 | 9.00 | 10.00 | 11.00 | 12.00 | 11.00 | 12.00 | 12.00 |
Liabilities | -1.3% | 38.00 | 38.00 | 40.00 | 41.00 | 46.00 | 49.00 | 41.00 | 46.00 | 22.00 | 24.00 | 26.00 | 28.00 | 32.00 | 39.00 | 18.00 | 17.00 | 18.00 | 23.00 | 22.00 | 20.00 | 21.00 |
Current Liabilities | -1.2% | 14.00 | 15.00 | 16.00 | 16.00 | 20.00 | 23.00 | 17.00 | 22.00 | 22.00 | 24.00 | 23.00 | 23.00 | 23.00 | 24.00 | 15.00 | 13.00 | 13.00 | 18.00 | 17.00 | 14.00 | 15.00 |
Shareholder's Equity | 66.6% | 211 | 126 | 144 | 164 | 184 | 212 | 143 | 162 | 186 | 208 | 223 | 238 | 253 | 132 | 22.00 | 41.00 | 56.00 | 80.00 | 109 | 76.00 | 99.00 |
Retained Earnings | -3.7% | -683 | -658 | -638 | -617 | -592 | -562 | -547 | -527 | -502 | -476 | -458 | -440 | -421 | -404 | -383 | -361 | -342 | -316 | -284 | -255 | -228 |
Additional Paid-In Capital | 13.8% | 894 | 785 | 783 | 781 | 777 | 774 | 691 | 689 | 688 | 685 | 681 | 678 | 674 | 537 | 405 | 403 | 399 | 396 | 393 | 332 | 328 |
Shares Outstanding | 85.6% | 38.00 | 20.00 | 20.00 | 20.00 | 20.00 | 20.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 7.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 52.00 | - | - | - | 46.00 | - | - | - | 272 | - | - | - | 73.00 | - | - | - | 101 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -21.0% | -25,200 | -20,823 | -17,897 | -27,465 | -27,995 | -34,480 | -20,429 | -15,878 | -27,190 | -20,874 | -18,424 | -17,100 | -21,366 | 1,307 | -15,564 | -13,068 | -29,274 | -21,245 | -19,241 | -26,301 | -25,927 |
Share Based Compensation | -16.9% | 1,611 | 1,938 | 1,625 | 1,944 | 2,118 | 1,587 | 1,524 | 1,814 | 2,612 | 3,415 | 3,416 | 3,635 | 2,907 | 2,518 | 2,764 | 3,243 | 3,104 | 3,404 | 3,392 | 3,911 | 3,500 |
Cashflow From Investing | -185.0% | -38,490 | 45,296 | -24,635 | -48,232 | 37,260 | 66,100 | 14,909 | -59,595 | 37,743 | 30,176 | -72,510 | -48,717 | -35.00 | -60.00 | -80.00 | 322 | 6,418 | 2,855 | 3,963 | 24,143 | -6,445 |
Cashflow From Financing | 21135.8% | 107,241 | 505 | - | - | - | 74,737 | -1.00 | 73.00 | 22.00 | 66.00 | 3.00 | -238 | 135,154 | - | - | - | - | -287 | - | - | - |
Condensed Consolidated Statements of Operations - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 18,873 | $ 24,631 |
General and administrative | 7,989 | 7,399 |
Total operating expenses | 26,862 | 32,030 |
Loss from operations | (26,862) | (32,030) |
Other income, net: | ||
Interest income | 2,651 | 1,799 |
Interest expense | (95) | (121) |
Other income, net | 3 | 282 |
Total other income, net | 2,559 | 1,960 |
Net loss | $ (24,303) | $ (30,070) |
Net loss per share, basic | $ (0.64) | $ (1.54) |
Net loss per share, diluted | $ (0.64) | $ (1.54) |
Weighted average shares of common stock outstanding, basic | 38,155,373 | 19,567,635 |
Weighted average shares of common stock outstanding, diluted | 38,155,373 | 19,567,635 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 117,574 | $ 74,015 |
Available-for-sale securities | 88,492 | 49,625 |
Prepaid expenses and other current assets | 8,126 | 6,094 |
Total current assets | 214,192 | 129,734 |
Operating lease, right-of-use assets | 26,098 | 26,539 |
Property and equipment, net | 6,391 | 6,624 |
Other non-current assets | 175 | 209 |
Restricted cash | 1,833 | 1,833 |
Total assets | 248,689 | 164,939 |
Current liabilities: | ||
Accounts payable | 1,730 | 2,032 |
Accrued expenses | 10,327 | 10,137 |
Operating lease liabilities | 1,694 | 1,855 |
Finance lease liabilities | 496 | 469 |
Other current liabilities | 92 | 24 |
Total current liabilities | 14,339 | 14,517 |
Operating lease liabilities, excluding current portion | 22,526 | 22,707 |
Finance lease liabilities, excluding current portion | 1,100 | 1,234 |
Total liabilities | 37,965 | 38,458 |
Commitments and contingencies (Note 11) | ||
Preferred stock, $0.001 par value - 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | ||
Common stock, $0.001 par value - 60,000,000 shares authorized; 37,833,689 and 20,386,606 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 38 | 20 |
Additional paid-in capital | 893,746 | 785,199 |
Accumulated other comprehensive (loss) income | (4) | 15 |
Accumulated deficit | (683,056) | (658,753) |
Total stockholders’ equity | 210,724 | 126,481 |
Total liabilities and stockholders’ equity | $ 248,689 | $ 164,939 |